|
WO2020112716A1
|
|
Inhibitors of influenza virus replication
|
|
TW202031293A
|
|
Formulations of influenza therapeutics
|
|
WO2020081751A1
|
|
Combinations of inhibitors of influenza virus replication
|
|
TW202023566A
|
|
Inhibitors of influenza virus replication
|
|
WO2020023813A1
|
|
Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
|
|
KR20210018806A
|
|
Combination therapy for treatment of HCV
|
|
MX2019012759A
|
|
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication.
|
|
WO2017075590A2
|
|
Processes for preparing 2-dihalo ribolactones
|
|
WO2016178876A2
|
|
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
|
TW201643147A
|
|
Inhibitors of hepatitis C virus polymerase
|
|
WO2016069975A1
|
|
2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
|
EP3134423A1
|
|
2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
|
MX2016013434A
|
|
Potent and selective inhibitors of hepatitis c virus.
|
